Concepedia

Maitreyee Hazarika

MH

7

Publications

721

Citations

7

H-Index

2002

Active since

Affiliations

Center for Drug Evaluation and Research(Current)

United States Food and Drug Administration

Maitreyee Hazarika is an author at Center for Drug Evaluation and Research specializing in oncology, medicine, and drug resistance.

Top concepts

Publications per year

2002–2018

7

Publications

7

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

Maitreyee Hazarika, Meredith K. Chuk, Marc R. Theoret et al. · Clinical Cancer Research · 2017 · 181 citations

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis

Julia A. Beaver, Maitreyee Hazarika, Flora Mulkey et al. · The Lancet Oncology · 2018 · 172 citations · Full text

, , +10

Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib

Maitreyee Hazarika, Xiaoping Jiang, Qi Liu et al. · Clinical Cancer Research · 2008 · 134 citations

Pemetrexed in Malignant Pleural Mesothelioma

Maitreyee Hazarika, Robert M. White, Brian Booth et al. · Clinical Cancer Research · 2005 · 109 citations · Full text

FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma

Amy Barone, Maitreyee Hazarika, Marc R. Theoret et al. · Clinical Cancer Research · 2017 · 86 citations

Rows per page

1–5 of 7